Kiniksa Pharmaceuticals International, Earnings Call Transcripts
Fiscal Year 2026
-
Strong commercial growth and expanded guidance for ARCALYST are supported by increasing prescriber adoption and a shift to chronic disease management. Pipeline assets KPL-387 and KPL-1161 are advancing, with key clinical milestones expected in 2024, and the company remains financially robust and focused on innovation.
-
Strong Q1 growth led to raised 2026 revenue guidance for ARCALYST, with expanding physician adoption and ongoing efforts to increase patient awareness. Pipeline progress includes KPL-387 phase II data expected in H2 and KPL-1161 entering phase I by year-end. Cash reserves remain robust at $468 million.
-
Q1 2026 saw ARCALYST revenue rise 56% year-over-year to $214.3M, driving net income to $22.6M and prompting a raised full-year revenue outlook. Strong commercial execution, new prescriber growth, and targeted DTC campaigns support continued momentum.
-
Strong revenue growth in 2025 was driven by increased patient numbers, prescriber engagement, and longer therapy duration, with significant market opportunity remaining. Pipeline progress includes upcoming Phase II data for KPL-387 and ongoing development of KPL-1161, supported by robust cash flow and a disciplined approach to expansion.
-
Significant revenue growth and market expansion were highlighted, with ARCALYST now established as the second-line standard of care for recurrent pericarditis. Pipeline progress includes KPL-387 in phase 2/3 trials and KPL-1161 entering the clinic by year-end, supporting a robust outlook.
Fiscal Year 2025
-
ARCALYST revenue surged 62% year-over-year to $677.6 million in 2025, with net income turning positive and strong cash generation. Pipeline progress continues with KPL-387 and KPL-1161, and 2026 revenue guidance is set at $900–$920 million.
-
ARCALYST continues robust growth with increased early adoption and strong 2025 revenue guidance. KPL-387, a monthly IL-1 inhibitor, advances in phase 2/3 trials, with high physician and patient interest and potential launch by 2028–2029.
-
Q3 2025 saw ARCALYST revenue surge 61% year-over-year to $180.9 million, driving a net income of $18.4 million and prompting a raised full-year sales guidance to $670–$675 million. Market adoption and prescriber growth remain strong, with KPL-387 advancing in development.
-
ARCALYST continues strong revenue growth with expanded prescriber base and increased patient duration, while new Medicare Part D policies provided a one-time boost. Pipeline programs KPL-387 and 1161 are advancing, with KPL-387 showing high physician and patient interest. Cash flow remains positive as development and commercialization efforts progress.
-
ARCALYST continues robust growth with strong revenue, expanding prescriber base, and high compliance. New guidelines and real-world data support its use, while KPL-387’s monthly dosing profile is poised to further expand the market. Innovation and global expansion remain strategic priorities.
-
Q2 net revenue rose 52% year-over-year to $156.8 million, driven by ARCALYST's strong commercial performance and expanded prescriber base. 2025 sales guidance was raised to $625–$640 million, and the KPL-387 Phase 2/3 trial is underway with data expected next year.
-
Strong ARCALYST growth and increased prescriber engagement drove higher 2024 revenue guidance and Q1 profitability. Medicare Part D redesign improved patient affordability, while pipeline assets KPL-387 and KPL-1161 advance, supporting long-term growth and lifecycle management.
-
Profitability and strong ARCALYST growth have enabled increased 2025 revenue guidance and robust cash reserves. KPL-387 is advancing with a phase II/III trial starting mid-2025, targeting a 2028–2029 launch. Education and broad payer coverage support further market expansion.
-
Q1 2025 saw Arcalyst revenue rise 75% year-over-year to $137.8M, with net income of $8.5M and strong prescriber growth. 2025 sales guidance was raised to $590–$605M, and the company remains cash flow positive, advancing its pipeline and expanding market reach.
-
The conference highlighted robust commercial growth, with ARCALYST achieving $416.4M in 2024 revenue and strong guidance for 2025. Strategic expansion, innovative clinical programs, and a shift in treatment paradigms position the company for continued success.
Fiscal Year 2024
-
KPL-387, a new monthly subcutaneous therapy for recurrent pericarditis, is advancing to Phase 2/3 trials, while ARCALYST delivered strong 2024 revenue growth and is projected to grow further in 2025. The company remains cash flow positive and is focusing on cardiovascular assets.
-
ARCALYST continues to show steady commercial growth, with increased duration of therapy and expanding prescriber base. The phase II-B study of abiprubart in Sjögren’s disease is progressing, targeting a large unmet need with a differentiated subcutaneous approach. Cash position remains strong at $223.8 million.
-
ARCALYST continues robust growth with expanding prescriber base, high payer approval, and increasing treatment duration. The addressable market may grow as earlier-stage patients are targeted, while pipeline progress and disciplined business development support future value creation.
-
Q3 2024 saw 73% year-over-year ARCALYST revenue growth to $112.2M, with increased prescriber adoption and repeat use. Full-year sales guidance was raised to $410–$420M, and the company remains cash flow positive with a strong financial position.
-
ARCALYST continues to drive steady growth in recurrent pericarditis, with increasing physician adoption, a shift to steroid-sparing management, and expanding patient identification. The pipeline asset abiprubart is advancing in Sjögren's, with differentiated dosing and potential for broader autoimmune indications.
-
Q2 2024 saw 90% year-over-year ARCALYST revenue growth, increased market penetration, and raised full-year sales guidance to $405–$415 million. The company advanced abiprubart into Phase 2b for Sjögren’s disease and expects to remain cash flow positive annually.
-
ARCALYST continues robust growth with 9% market penetration and strong compliance, supported by expanded field teams and patient programs. Pipeline progress includes a phase IIb trial in Sjögren's and ongoing business development, all underpinned by a strong cash position and disciplined capital allocation.